Expression of Survivin, PTEN and P53 in Endometrial Carcinoma and Their Relationship
秦赟娜,于晓红,路名芝,魏宝秀,付秋风,揭由坤,邓颖辉
DOI: https://doi.org/10.3969/j.issn.1001-7399.2008.02.011
2008-01-01
Abstract:Purpose To study the expression of survivin and PTEN, p53 in endometrial carcinoma and to explore their significance and correlation. Methods Immunohistochemical EliVision method was used to detect the expression of survivin, PTEN, and p53 in 86 cases of endometrial carcinoma, 30 cases of atypical hyperplasia of endometrium and 30 cases of normal endometrium. Results The positive rates of survivin immunostaining in endometrial carcinoma, atypical hyperplasia of endometrium and normal endormetrium were 76.7%, 40.0% and 13.3%, respectively, there being significant difference between the three groups (P0.01). The positive rates of PTEN in endometrial carcinoma, atypical hyperplasia of endometrium and normal endometrium were 40.7%, 60.0% and 100.0%, respectively, there being significant difference (P0.01), but no statistical difference between the former two (P0.05). The positive rates of p53 in endometrial carcinoma, atypical hyperplasia of endometrium and normal endometrium were 43.0%, 20.0% and 0 respectively, there being significant difference between the three groups (P0.01). The positive expression of survivin and PTEN was not correlated with histological grade, invasive to myometrium and clinicopathological stage, but the expression of p53 was obviously correlated with the above. The expression of PTEN and p53 was obviously correlated with the histological type, but survivin not. There was positively related between the expression of survivin and p53 in endometrial carcinoma, coefficient of ranked correlation (rs=0.367,P0.01), and negatively related between the expression of survivin and PTEN (rs=-0.384, P0.01). Conclusions survivin, PTEN and p53 may play certain roles in oncogensis and progression of endometrial carcinoma to different extent. Detection of survivin together with PTEN and p53 is valuable for early diagnosis and evaluation of prognosis for endometrial carcinoma.